Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    thumbnails
    Download 2025 Global and China biotech sector survey reports

    Two new reports of surveys of 260+ Global and China biotech leaders have just been released

    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

    data network
    Riding the data wave: How pharma can navigate disruptions in open claims

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 469 - 480 of 1015 results for "*"

ICON Plc facebook post
ICON Plc logo
ICON Plc

By 2050, the number of people living with diabetes is projected to rise to 853 million. In the past 5 years, ICON has conducted 198 metabolic studies involving 50,000+ patients and healthy volunteers at 8,600+ sites, inc...

14 Nov
3
Social media image
ICON Plc logo
ICON Plc

This World Diabetes Day, the theme ‘Diabetes and the workplace’ reminds us that 70% of people living with diabetes are of working age. At ICON, we recognise the urgency of advancing therapies that improve outcomes for t...

14 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Flexible, risk-based monitoring strategies are transforming global trial delivery. ICON’s new whitepaper shows how smarter oversight improves quality, reduces cost and accelerates timelines. Download now: https://www.ico...

14 Nov
1
Social media image
ICON Plc logo
ICON Plc

Flexible, risk-based monitoring strategies are transforming global trial delivery. ICON’s new whitepaper shows how smarter oversight improves quality, reduces cost and accelerates timelines. Download now: https://lnkd.in...

14 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

14 Nov
4
Social media image
ICON Plc logo
ICON Plc

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

14 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

In the dynamic world of life sciences, the consultancy sector is undergoing a transformation as cost pressures increase, speed to market needs accelerate and technology permeates every aspect. Against this backdrop, clie...

13 Nov
2
Social media image
ICON Plc logo
ICON Plc

Customer advocacy is not a trend, it’s a transformation. It represents a shift from service to stewardship and from expertise to empathy. It’s about recognising that behind every clinical milestone, every regulatory su...

13 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Use Journals & Congresses to sort over 10,000 journals and congresses by submission date and lead times. Get your answer quickly so you can focus on your work. See how easy it is for yourself & request a demo. https://ow...

13 Nov
1
Social media image
ICON Plc logo
ICON Plc

Use Journals & Congresses to sort over 10,000 journals and congresses by submission date and lead times. Get your answer quickly so you can focus on your work. See how easy it is for yourself & request a demo. https://ow...

13 Nov
ICON Plc facebook post
ICON Plc logo
ICON Plc

Biosimilars are gaining ground in APAC — but adoption depends on education. ICON’s latest blog dives into the real-world barriers to biosimilar uptake across Asia-Pacific, from low patient awareness to prescriber miscon...

13 Nov
2
Social media image
ICON Plc logo
ICON Plc

Biosimilars are positively impacting healthcare in APAC — but awareness and trust remain critical hurdles. ICON explores how strategic education and engagement can unlock biosimilar adoption across Asia-Pacific, from em...

13 Nov
  • Previous
  • 1
  • …
  • 39
  • 40
  • 41
  • …
  • 85
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence